Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05749848 · ClinicalTrials.gov registry record · Phase 1
A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05749848 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 8 participants.
The verdict
NCT05749848, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate how much of the study drug (LY3372689), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last about 4 weeks. Screening is required within 28 days prior to the start of the study and follow up is required approximately 7 days after discharge.
Interventions
- DRUG [¹⁴C]-LY3372689
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-02-24 |
| Est. Completion | 2023-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05749848
The ClinicalTrials.gov registry entry for NCT05749848 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [¹⁴C]-LY3372689 is the first listed.
NCT05749848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05749848 about?
NCT05749848 is a clinical study titled "A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants". The main purpose of this study is to evaluate how much of the study drug (LY3372689), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of t...
What is the current status of trial NCT05749848?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-02-24. Estimated completion is 2023-04-18.
What interventions are being tested in trial NCT05749848?
The interventions under investigation include: [¹⁴C]-LY3372689 (DRUG).
Who is sponsoring clinical trial NCT05749848?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.